Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

FEBS letters - 1 May 2006

Hanna Nadine, Montagner Alexandra, Lee Wen Hwa, Miteva Maria, Vidal Michel, Vidaud Michel, Parfait Béatrice, Raynal Patrick

Abstract excerpt

LEOPARD (LS) and Noonan (NS) are overlapping syndromes associated with distinct mutations of SHP-2. Whereas NS mutations enhance SHP-2 catalytic activity, we show that the activity of three representative LS mutants is undetectable when assayed using a standard protein tyrosine phosphatase (PTP) substrate. A different assay using a specific SHP-2 substrate confirms their decreased PTP activity, but also reveals a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalysis
Share to Chlorocebus aethiops

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermal Growth Factor

Share to LEOPARD Syndrome

Share to Phosphatidylinositol 3-Kinases

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Protein Tyrosine Phosphatases

Share to Vero Cells

Source

Identifiers

PMID: 16638574
DOI: 10.1016/j.febslet.2006.03.088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.PMID 16638574Read ↗

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.Semantic proximity Read ↗

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).Semantic proximity Read ↗

Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling.Semantic proximity Read ↗

Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.Semantic proximity Read ↗

Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.Semantic proximity Read ↗

Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome PathogenesisSemantic proximity Read ↗

SHP2 sails from physiology to pathology.Semantic proximity Read ↗

Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.Semantic proximity Read ↗

How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?Semantic proximity Read ↗

Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.Semantic proximity Read ↗

A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.Semantic proximity Read ↗

Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.